Global Point of Care
Home > Products

Determine™ TB LAM Ag

Rapid Rule-in TB-HIV co-infection

The Determine™ TB LAM Ag test empowers you, at the point-of-care, to screen for active TB in HIV positive patients, providing results in just minutes.

This rapid test detects the LAM antigen (lipoarabinomannan) in urine samples, assisting you in your TB screening to rule-in sooner than traditional methods and enabling earlier treatment for your patient.

Benefits
  • The Determine™ TB LAM Ag test empowers you, at the point-of-care, to screen for active TB in HIV positive patients, providing results in just minutes.
  • Offers optimal performance in HIV positive patients with advanced immunosuppression.
  • A useful tool for detecting sputum smear negative patients.
  • Diagnose both pulmonary and extra pulmonary TB from one convenient urine sample.
  • Enhanced power comes through combination with methods such sputum smear microscopy or the Xpert® MTB/RIF test.
  • Uses unprocessed urine as the validated sample type.
  • LAM, lipoarabinomannan, is a structurally important component of the outer cell wall of mycobacteria that is shed from metabolically active or degrading cells, is cleared by the kidney and detectable in urine.
  • Results in 25 minutes.
Helpful Documents

PRODUCT INFORMATION

Method
Time to results
Storage conditions
Sample type
Kit contents

 

Lateral flow
25 mins.
2 – 30°C
Urine (unprocessed)
25 test units
Reference Scale Card
Package Insert

PERFORMANCE

Specificity1

Sensitivity1 (%)
4.0%
39.0%
45.7%
51.7%
66.7%

> 98%

CD4 cell count
(cells/µL)
≥ 200
< 200
< 150
< 100
< 50
Determine™ TB LAM Ag
 Code
Determine™ TB LAM Ag 25 tests
 7D2741

For Australia prefix code with DT

Related Products
Alere Determine HIV-1/2 Ag/Ab Combo
Determine™ HIV-1/2 Ag/Ab Combo
  1. Lawn SD, Kerkhoff AD, Vogt M, Wood R. Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: a descriptive study. Lancet Infect Dis. 2012 Mar;12(3):201-9.

Stay informed

Sign up to receive valuable updates from Abbott.